Alexandria Real Estate Equities (ARE) Investor Day 2024 summary

Strategic positioning and business model

• Focus on mega campus strategy, aiming to increase portfolio share from 76% to 90% by 2029, emphasizing irreplaceable locations, scale, and industry relationships for long-term growth.

• Mega campuses provide flexibility, robust amenities, and operational excellence, resulting in high occupancy, rental premiums, and tenant retention rates above 80%.

• The company has a 30-year track record of navigating market cycles, prioritizing disciplined capital allocation and long-term value creation.

• Commitment to innovation and sustainability, including LEED Platinum buildings and renewable energy projects, supports industry leadership.

Financial guidance and capital allocation

• 2025 FFO per share guidance is $9.23–$9.43, essentially flat compared to 2024, with a temporary dip due to lease expirations and ground lease extension costs.

• $510 million in incremental annual NOI expected from pipeline deliveries through Q1 2028, with 55% of the active pipeline already leased or under negotiation.

• Capital needs for 2025 will be self-funded primarily through retained cash flows, dispositions, and joint ventures, with no public equity issuance planned.

• Dispositions in 2025 are expected to be around $1.55 billion, focusing on non-core assets, with cap rates in the low to mid 7% range.

• Construction spending will decline to $1.75 billion in 2025, with 58% allocated to active projects and 23% to pre-construction on future mega campus developments.

Market environment and leasing dynamics

• The company outperforms competitors in leasing, with 2024–2025 deliveries in major markets 99% leased versus 39% for competitive supply.

• Mega campuses command 10–20% rental rate premiums and offer tenants liquidity and flexibility for growth or downsizing.

• Public biotech leasing is at a historic low (~7% of activity), but expected to rebound as market conditions improve; tenant retention remains above 80%.

• Institutional investor interest in life science real estate remains strong, with a flight to quality benefiting the company’s core assets.